A 34-year-old male presented to the Otorhinolaryngology Outpatient Clinic with primary complaint of non-specific neck pain and was found to have left-sided submandibular lymphadenopathy on physical examination. A fine needle aspiration biopsy (FNAB) of the lymph nodes (LN) was performed. An initial diagnosis of malignant salivary gland neoplasm was made. To further delineate the tumor location, magnetic resonance imaging (MRI) of the neck was done. It revealed pathologically enlarged LN; however, no abnormalities in the salivary glands were noticed (Fig. 1). Therefore, PET scan with $^{18}$F-FDG was carried out to locate the primary tumor site. It revealed an active metabolic process in several LNs of the upper and middle neck regions (Fig. 2). In light of these imaging studies, the patient was taken for bilateral tonsillectomy, adenoidectomy, and selective neck dissection of level II LNs. Histopathological examination revealed macro-metastasis of medullary thyroid carcinoma (MTC) in these lymphoid tissues. On immunohistochemistry, the specimens stained positively for synaptophysin, chromogranin A, and calcitonin. Meanwhile, the serum calcitonin level was 300 ng/mL.

With the suspicion of thyroid cancer, a multidisciplinary discussion was held, which qualified the
patients for a radical thyroidectomy with radical neck dissection. The resected specimens were evaluated by two experienced histopathologists, which resulted in identification of multifocal papillary thyroid carcinoma (PTC) in the thyroid gland (pT1a[m]N0) and positive MTC metastases in central and left-sided LNs (levels II–IV). Congruent to MRI and PET scan, histopathological examination also failed to determine the site of primary MTC tumour (pT1xN1b) (Fig. 3, 4).

The postoperative period was uneventful. MEN2 syndrome was excluded on the basis of negative MRI for pheochromocytoma and negative genetic tests for RET and BRAF mutations. On one-year follow-up, the patient was doing well with serum calcitonin level below 2 pg/mL.

Simultaneous medullary (MTC) and papillary thyroid carcinoma is extremely rare [1]. To our knowledge, such coexistence without the identification of a primary tumour site for either carcinoma has never been reported. In our case, the primary origin of MTC was not identified even after extensive imaging tests and histopathological examination of thyroidectomy specimen (by two experienced pathologists). When a diligent search fails to disclose the primary lesion, then the metastatic disease is classified as “carcinoma of unknown primary” syndrome [2]. This may have occurred in our case, because the primary MTC was small in size, induced metastasis, and then regressed completely while metastatic lesion proliferated in the LNs [3].

**References**